The University of Michigan has officially ceased operations in all its Biosafety Level 3 (BSL-3) laboratories. This significant shift follows the U.S. Centers for Disease Control and Prevention’s updated containment guidelines for SARS-CoV-2 research, issued in March 2025. As a leading institution in biological research, this transition marks a notable change in the university’s approach to handling high-risk pathogens.
Understanding BSL-3 Laboratories
BSL-3 laboratories are specially designed to manage highly infectious and potentially lethal viruses, such as SARS-CoV-2, HIV, and tuberculosis. These facilities adhere to stringent safety protocols to minimize the risk of exposure. They are equipped with directional airflow systems, dual-door airlock entries, and sealed surfaces to ensure a controlled environment. Additionally, decontamination processes for waste and equipment are essential components of BSL-3 operations, along with medical surveillance for staff.
The classification of biosafety levels ranges from BSL-1, which handles low-risk microbes like E. coli K-12, to BSL-4, which deals with the deadliest pathogens, such as the Ebola virus and smallpox. This tiered system is crucial for determining appropriate safety practices based on the risk posed by different pathogens.
The Impact of COVID-19
During the early stages of the COVID-19 pandemic, the CDC mandated that research involving live SARS-CoV-2 virus be conducted in BSL-3 facilities. This requirement stemmed from limited knowledge regarding the virus’s transmissibility and severity. However, with the advent of vaccines and a deeper understanding of SARS-CoV-2, the CDC revised these guidelines in March 2025, allowing research to proceed under enhanced BSL-2 conditions.
Philip Hanna, chair of the Institutional Biosafety Committee (IBC) at UMich, noted that the university’s BSL-3 labs had pivoted entirely to COVID-19 research since early 2020. This shift halted all other infectious disease studies, illustrating the pandemic’s overwhelming priority in the research landscape.
Transitioning to Enhanced BSL-2
In light of the revised guidance, the university downgraded its BSL-3 laboratory spaces to meet enhanced BSL-2 standards. Jacqueline Shields, associate director of Research Safety Compliance, confirmed that, as of late October 2023, there are no operational BSL-3 labs at the university. However, research on SARS-CoV-2 continues in designated enhanced BSL-2 spaces.
The cessation of BSL-3 operations raises questions about the future of research on other high-consequence pathogens, such as anthrax and malaria. While some researchers previously involved in BSL-3 projects have redirected their work, the extent and nature of ongoing research in the absence of BSL-3 facilities remain unclear.
Ongoing Research Opportunities
Despite the discontinuation of BSL-3 lab work, UMich researchers continue to utilize BSL-1 and BSL-2 facilities for various studies. Andrew Tai, a member of the IBC and associate professor of internal medicine, has transitioned from SARS-CoV-2 research in a BSL-3 lab to studying Zika and Dengue viruses in a BSL-2 environment. This transition has alleviated some procedural burdens and allowed for a broader focus on different pathogens.
For many researchers, the shift has resulted in a more manageable research landscape. Tai emphasized the rigorous inspection processes associated with BSL-3 facilities, which included thorough audits by both institutional and federal agencies.
Safety Measures and Best Practices
Safety remains a top priority in all laboratory settings. Ulises Perez, a Rackham student and member of the BSL-1 Biteen Lab, outlined the importance of maintaining sterile techniques and safety protocols in his day-to-day tasks. Lab members regularly practice safety measures and undergo training to ensure a secure working environment.
University spokesperson Brian Taylor highlighted the institution’s commitment to research while maintaining strict safety oversight. The university’s approach involves rigorous assessments from multiple departments and agencies, ensuring that all necessary safeguards, including training and engineering controls, are in place to protect personnel and the community.
Future Directions in Research
As UMich navigates this new chapter without BSL-3 labs, the focus on enhanced BSL-2 facilities will likely shape the future of research on infectious diseases. Continued advancements in understanding pathogens and their dynamics will be critical, as the landscape of infectious disease research evolves in response to ongoing global health challenges.
In conclusion, the University of Michigan’s decision to phase out BSL-3 lab operations signifies a pivotal moment in its research trajectory. While the future of high-consequence infectious disease research may look different, the university remains committed to advancing knowledge and ensuring safety in its ongoing scientific endeavors.
- The University of Michigan has ceased operations in all BSL-3 laboratories.
- The shift follows updated CDC guidelines allowing SARS-CoV-2 research under enhanced BSL-2 conditions.
- Researchers continue to study various pathogens using BSL-1 and BSL-2 facilities.
- Safety and compliance remain paramount, with stringent oversight in place.
- The transition reflects the evolving landscape of infectious disease research post-COVID-19.
Read more → www.michigandaily.com